Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 7, 2026, 1:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 461 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Plaque Psoriasis Clear all
Completed Phase 3 Interventional Results available

Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis

NCT03589885
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Placebo 2 mL auto-injector, Placebo 1 mL prefilled syringe, Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
8
States / cities
Miami, Florida • Marietta, Georgia • Saint Joseph, Missouri + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 10, 2021 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

Preference Between Two Autoinjectors in Patients With Rheumatoid Arthritis and Plaque Psoriasis Treated With Etanercept

NCT01875991
View directory record Official record
Conditions
Rheumatoid Arthritis, Plaque Psoriasis
Interventions
Etanercept via Autoinjector A, Etanercept via Autoinjector B
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
217 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
28
States / cities
Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 25 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2018 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

A Comparison of 188-0551 Spray Versus Vehicle Spray in Subjects With Plaque Psoriasis

NCT03759197
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
188-0551 Spray, Vehicle Spray
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
206 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
12
States / cities
Fort Smith, Arkansas • Fountain Valley, California • Fremont, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Multicenter Study of 074-6751 Lotion in Subjects With Moderate Plaque Psoriasis

NCT03167515
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
074-6751 Lotion
Device
Lead sponsor
Ferndale Laboratories, Inc.
Industry
Eligibility
18 Years and older
Enrollment
95 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
5
States / cities
Tampa, Florida • Carmel, Indiana • Plainfield, Indiana + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 11, 2018 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

A Study of Escalating Doses of Itacitinib Administered Orally in Patients With Plaque Psoriasis

NCT01634087
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Itacitinib, Placebo
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hot Springs, Arkansas • Los Angeles, California • Clinton, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2019 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Study of Guselkumab in Skin of Color Participants With Moderate-to-severe Plaque and/or Scalp Psoriasis

NCT05272150
View directory record Official record
Conditions
Plaque Psoriasis, Scalp Psoriasis
Interventions
Guselkumab, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
79
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 67 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 7, 2026, 1:04 PM EDT
Terminated Phase 4 Interventional Results available

Taclonex Ointment With Hydrogel Patch Occlusion for the Treatment of Psoriasis

NCT00924950
View directory record Official record
Conditions
Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Taclonex Ointment and Hydrogel Patch, Taclonex Ointment
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 17, 2019 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet

NCT00585650
View directory record Official record
Conditions
Psoriasis
Interventions
Etanercept, Placebo injections
Biological · Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
3
States / cities
Irvine, California • Winston-Salem, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 17, 2023 · Synced Sep 7, 2026, 1:04 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ASC50 Tables in Healthy Participants and Participants With Plaque Psoriasis

NCT07024602
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
ASC50 tablets or matching placebo
Drug
Lead sponsor
Ascletis Pharma (China) Co., Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jun 16, 2025 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Open Label Continuation Study in Moderate to Severe Psoriasis

NCT00626002
View directory record Official record
Conditions
Moderate to Severe Plaque Psoriasis
Interventions
ABT-874
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
2,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
98
States / cities
Birmingham, Alabama • Huntsville, Alabama • Scottsdale, Arizona + 80 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2013 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Study to Assess if Mirikizumab is Effective and Safe Compared to Secukinumab and Placebo in Moderate to Severe Plaque Psoriasis (OASIS-2)

NCT03535194
View directory record Official record
Conditions
Psoriasis
Interventions
Mirikizumab, Placebo, Secukinumab
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,484 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
42
States / cities
Birmingham, Alabama • Bakersfield, California • Beverly Hills, California + 37 more
Source: ClinicalTrials.gov public record
Updated Mar 29, 2021 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Efficacy and Safety of Prurisol Administered Orally for Active Mild to Moderate Chronic Plaque Psoriasis

NCT02494479
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Prurisol, Placebo
Drug
Lead sponsor
Cellceutix Corporation
Industry
Eligibility
18 Years and older
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
9
States / cities
Huntsville, Alabama • Encino, California • Coral Gables, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2017 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 2 Interventional

Topical SGX302 for Mild-to-Moderate Psoriasis

NCT05442190
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis, Psoriasis Vulgaris
Interventions
Hypericin
Drug
Lead sponsor
Soligenix
Industry
Eligibility
18 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 7, 2026, 1:04 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis

NCT02502188
View directory record Official record
Conditions
Parapsoriasis, Healthy Volunteers
Interventions
CC-90005, Placebo
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT00235820
View directory record Official record
Conditions
Psoriasis
Interventions
adalimumab, MTX, placebo adalimumab, placebo MTX
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years and older
Enrollment
271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Abbott Park, Illinois
Source: ClinicalTrials.gov public record
Updated Jul 16, 2008 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 1 Interventional

Study to Evaluate the Pharmacokinetics and the Safety of M518101 in Plaque Psoriasis Patients

NCT01844973
View directory record Official record
Conditions
Psoriasis
Interventions
M518101, Vehicle
Drug
Lead sponsor
Maruho North America Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2013 · Synced Sep 7, 2026, 1:04 PM EDT
Recruiting Phase 4 Interventional

A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis

NCT03987763
View directory record Official record
Conditions
Psoriasis
Interventions
IDP-122 Lotion
Drug
Lead sponsor
Bausch Health Americas, Inc.
Industry
Eligibility
6 Years to 17 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
7
States / cities
Fountain Valley, California • Thousand Oaks, California • Doral, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2025 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab

NCT04102007
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
244 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Hot Springs, Arkansas • North Little Rock, Arkansas + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2023 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Not applicable Interventional

LCD Solution Versus Calcipotriol Cream in the Treatment of Moderate Plaque Psoriasis

NCT00705900
View directory record Official record
Conditions
Chronic Plaque Psoriasis
Interventions
LCD, calcipotriol
Drug
Lead sponsor
NeoStrata Company, Inc.
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 18, 2008 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

Comparison of CHS-0214 to Enbrel (Etanercept) in Patients With Chronic Plaque Psoriasis (PsO)

NCT02134210
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Etanercept, CHS-0214
Drug
Lead sponsor
Coherus Oncology, Inc.
Industry
Eligibility
18 Years and older
Enrollment
521 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
50
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Anaheim, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

NCT03370133
View directory record Official record
Conditions
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions
Bimekizumab, Ustekinumab, Placebo
Drug · Other
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
567 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
25
States / cities
Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional

A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis

NCT06973291
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Zasocitinib, Deucravacitinib, Placebo to match zasocitinib, Placebo to match deucravacitinib
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
606 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
31
States / cities
Fort Smith, Arkansas • Hot Springs, Arkansas • Beverly Hills, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age

NCT02698475
View directory record Official record
Conditions
Psoriasis
Interventions
Ustekinumab 0.75 mg/kg, Ustekinumab 45 mg, Ustekinumab 90 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
6 Years to 11 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
7
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2021 · Synced Sep 7, 2026, 1:04 PM EDT
Completed Phase 4 Interventional Results available

A Study to Evaluate the Efficacy and Tolerability of Topical Therapies for the Condition of Plaque-Type Psoriasis

NCT00852761
View directory record Official record
Conditions
Plaque-Type Psoriasis
Interventions
Olux-E Foam, Clobex lotion
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 22, 2012 · Synced Sep 7, 2026, 1:04 PM EDT